dupilumab
regeneron,sanofi
['dupixent', 'dupilumab', '$regn']
$regn [15s. delayed]: issued press release on september 08, 11:29:00: dupixent (dupilumab) late-breaking phase 3 data at the eadv 2022 congress showed significant improvements in signs and symptoms of prurigo nodularis 
Flash Alert is a low-latency financial news service which sources SEC, press releases, credible news sources to get your news about stocks in near real-time